September 2023 Top Biopharma Deal Upfront
September 11, 2023
$1,820M
$120M
n/a
n/a
$1,700M
Undisclosed
n/a
TCR bispecifics (TCER)
Development and Commercialization License
Co-Development, Shared Dev Cost , Options to Add Products, TAs, and/or Territories
Congrats to Immatics and Moderna for landing DealForma’s September 2023 Top Biopharma Deal. Last month’s Deal of the Month was Poseida – Astellas for P-MUC1C-ALLO1. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive